NO20002998L - Purinderivater som har fosfodiesterase IV inhibisjonsaktivitet - Google Patents

Purinderivater som har fosfodiesterase IV inhibisjonsaktivitet

Info

Publication number
NO20002998L
NO20002998L NO20002998A NO20002998A NO20002998L NO 20002998 L NO20002998 L NO 20002998L NO 20002998 A NO20002998 A NO 20002998A NO 20002998 A NO20002998 A NO 20002998A NO 20002998 L NO20002998 L NO 20002998L
Authority
NO
Norway
Prior art keywords
alkyl
optionally substituted
cycloalkylalkyl
cycloalkenyl
cycloalkyl
Prior art date
Application number
NO20002998A
Other languages
English (en)
Norwegian (no)
Other versions
NO20002998D0 (no
Inventor
David J Cavalla
Mark Chasin
Peter Hofer
Andre Gehrig
Peter Wintergerst
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of NO20002998D0 publication Critical patent/NO20002998D0/no
Publication of NO20002998L publication Critical patent/NO20002998L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28Oxygen atom
    • C07D473/30Oxygen atom attached in position 6, e.g. hypoxanthine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)
NO20002998A 1997-12-12 2000-06-09 Purinderivater som har fosfodiesterase IV inhibisjonsaktivitet NO20002998L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6937197P 1997-12-12 1997-12-12
PCT/US1998/026293 WO1999031102A1 (en) 1997-12-12 1998-12-11 Purine derivatives having phosphodiesterase iv inhibition activity

Publications (2)

Publication Number Publication Date
NO20002998D0 NO20002998D0 (no) 2000-06-09
NO20002998L true NO20002998L (no) 2000-07-19

Family

ID=22088545

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002998A NO20002998L (no) 1997-12-12 2000-06-09 Purinderivater som har fosfodiesterase IV inhibisjonsaktivitet

Country Status (19)

Country Link
US (5) US6040447A (de)
EP (3) EP1044201A4 (de)
JP (5) JP2002508378A (de)
KR (3) KR100349385B1 (de)
CN (3) CN1294590A (de)
AT (1) ATE244243T1 (de)
AU (5) AU1722899A (de)
BR (3) BR9815170A (de)
CA (3) CA2313004A1 (de)
DE (3) DE19882893T1 (de)
DK (1) DK1045849T3 (de)
ES (1) ES2202924T3 (de)
GB (2) GB2346879B (de)
HU (3) HUP0301166A2 (de)
NO (1) NO20002998L (de)
PL (1) PL341108A1 (de)
PT (1) PT1045849E (de)
TR (1) TR200001706T2 (de)
WO (5) WO1999031105A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002541078A (ja) * 1999-04-02 2002-12-03 ユーロ−セルティーク,エス.エー. ホスホジエステラーゼiv阻害活性を有するプリン誘導体
EP1202628B1 (de) * 1999-08-12 2004-10-13 Euro-Celtique S.A. Hypoxanthin- und thiohypxanthin-verbindungen
US7342021B2 (en) * 2001-02-08 2008-03-11 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
FR2842809A1 (fr) * 2002-07-26 2004-01-30 Greenpharma Sas NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
AU2003264017B2 (en) * 2002-08-08 2010-05-27 Memory Pharmaceuticals Corporation Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors
JP2005538133A (ja) * 2002-08-08 2005-12-15 メモリー・ファーマシューティカルズ・コーポレイション ホスホジエステラーゼ4阻害剤
US20040063938A1 (en) * 2002-09-30 2004-04-01 Pfizer Inc Process for preparing haloalkyl pyrimidines
OA13187A (en) * 2003-07-10 2006-12-13 Achillion Pharmaceuticals Inc Substituted arylthiourea derivatives useful as inhibitors of viral replication.
TW200523262A (en) * 2003-07-29 2005-07-16 Smithkline Beecham Corp Inhibitors of AKT activity
EP1697363A2 (de) * 2003-12-16 2006-09-06 Ranbaxy Laboratories Limited Als phosphodiesterase-(pde-)typ-iv-inhibitoren verwendbare purinverbindungen
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
EP1940389A2 (de) 2005-10-21 2008-07-09 Braincells, Inc. Modulation von neurogenese durch pde-hemmung
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US7625890B2 (en) 2005-11-10 2009-12-01 Smithkline Beecham Corp. Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
EP2021000A2 (de) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenese mittels angiotensin-modulation
DE102006033572A1 (de) 2006-07-20 2008-01-24 Bayer Cropscience Ag N'-Cyano-N-halogenalkyl-imidamid Derivate
EP2068872A1 (de) 2006-09-08 2009-06-17 Braincells, Inc. Kombinationen mit einem 4-acylaminopyridin-derivat
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
US20110027803A1 (en) 2007-12-17 2011-02-03 Artin Moussavi Compositions and Methods for Maintenance of Fluid Conducting and Containment Systems
PE20120003A1 (es) * 2009-01-30 2012-02-12 Glaxosmithkline Llc Hidrocloruro de n-{(1s)-2-amino-1-[(3-fluorofenil)metil)etil}-5-cloro-4-(4-cloro-1-metil-1h-pirazol-5-il)-2-tiofenocarboxamida cristalino
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9012450B2 (en) 2011-12-28 2015-04-21 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
CN104135859B (zh) 2011-12-28 2017-06-27 全球血液疗法公司 取代的苯甲醛化合物及其用于增加组织氧合的方法
EP2804603A1 (de) 2012-01-10 2014-11-26 President and Fellows of Harvard College Betazellen-replikation für promoterverbindungen und verwendungsverfahren dafür
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AP2015008721A0 (en) 2013-03-15 2015-09-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
PE20160078A1 (es) 2013-03-15 2016-03-02 Global Blood Therapeutics Inc Compuestos y sus usos para modular la hemoglobina
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
MY183637A (en) 2013-03-15 2021-03-04 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
PT3102208T (pt) 2014-02-07 2021-04-05 Global Blood Therapeutics Inc Polimorfos cristalinos da base livre de 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3 il)metoxi)benzaldeído
TW201731509A (zh) 2015-12-04 2017-09-16 全球血液治療公司 針對2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之劑量方案
WO2017123766A1 (en) * 2016-01-12 2017-07-20 Sperovie Biosciences, Inc. Compounds and compositions for the treatment of disease
AR108435A1 (es) 2016-05-12 2018-08-22 Global Blood Therapeutics Inc Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
US11014884B2 (en) 2018-10-01 2021-05-25 Global Blood Therapeutics, Inc. Modulators of hemoglobin
RU2746012C2 (ru) * 2019-05-13 2021-04-05 Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации ФГБОУ ВО ВолгГМУ МЗ РФ Антидепрессантное средство для коррекции нежелательных побочных эффектов нейролептиков

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2903455A (en) 1959-09-08 Jdnviiiiaisnvhi jo
US2956998A (en) 1960-10-18 Adenine derivatives and process
US3215696A (en) 1965-11-02 Substituted adenines -and preparation thereof
US2844577A (en) 1958-07-22 Certificate of correction
US2697709A (en) 1951-06-14 1954-12-21 Burroughs Wellcome Co Mercapto heterocycles and method of making
US2691654A (en) 1952-06-11 1954-10-12 Buroughs Wellcome & Co U S A I Amino heterocycles and method of making
US2966488A (en) 1956-07-30 1960-12-27 Shive William Substituted alkylaminopurines
US2957875A (en) 1957-11-18 1960-10-25 Upjohn Co Derivatives of purine
US3079378A (en) 1960-02-01 1963-02-26 Upjohn Co Acylated psicofuranosyladenines
BE601946A (de) 1960-03-31
US3135753A (en) 1961-05-10 1964-06-02 Burroughs Wellcome Co Alkylthiopurines and method
FR1548252A (de) 1961-10-13 1968-12-06
IL24679A (en) * 1965-11-24 1971-10-20 Yissum Res Dev Co Derivatives of 3-methyl purine and methods of preparing the same
US3669979A (en) 1967-12-14 1972-06-13 Gaf Corp Novel process for the production of 2-benzothiazolyl-phenol and derivatives thereof employing phosphorus trichloride as a catalyst
US3952001A (en) 1970-07-01 1976-04-20 The Boots Company Limited 1-Carbamoyl-1,2,4-triazoles
JPS5121529A (ja) 1974-08-16 1976-02-20 Hitachi Ltd Pirorinsandometsukizeiseihimakuboshiho
USRE31429E (en) 1977-02-14 1983-10-25 Merck & Co., Inc. Process for preparation of 9-(dihalobenzyl)adenines
GB2041359B (en) 1979-01-10 1982-12-15 Ici Ltd Purine derivatives and their use in the defoliation of cotton plants
US4241063A (en) 1979-08-06 1980-12-23 Bristol-Myers Company Purine derivatives and their use as bronchodilators
US4361699A (en) 1981-09-28 1982-11-30 Merck & Co., Inc. Novel process for the preparation of N6 -alkyl-arprinocid
US4407802A (en) 1981-09-28 1983-10-04 Merck & Co., Inc. 6-Amidino-9-substituted benzyl purines
GB2120065B (en) 1982-04-27 1986-01-02 Michael Frederick Huber Heating plants
US4492592A (en) 1983-06-06 1985-01-08 Shell Oil Company Combined desiccation of substantially supercritical CO2
JPS60260579A (ja) 1984-01-13 1985-12-23 Yoshitomi Pharmaceut Ind Ltd プリン誘導体
US4883801A (en) 1984-09-07 1989-11-28 The General Hospital Corporation Xanthine derivative pest control agents
GB8510758D0 (en) 1985-04-27 1985-06-05 Wellcome Found Compounds
HU215433B (hu) 1986-04-29 2000-05-28 Pfizer Inc. Eljárás új 2-oxo-5-fenil-pirimidin-származékok előállítására
GB8618931D0 (en) 1986-08-02 1986-09-10 Euro Celtique Sa 6-thioxanthines
US5057517A (en) 1987-07-20 1991-10-15 Merck & Co., Inc. Piperazinyl derivatives of purines and isosteres thereof as hypoglycemic agents
US5091431A (en) 1988-02-08 1992-02-25 Schering Corporation Phosphodiesterase inhibitors
EP0363320A3 (de) 1988-10-06 1991-11-21 Ciba-Geigy Ag Substituierte 9H-Purine
US4971972A (en) 1989-03-23 1990-11-20 Schering Corporation Phosphodiesterase inhibitors having an optionally substituted purine derivative portion and a benzo- or cyclopenta-furan portion
US5290782A (en) 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
EP0423805B1 (de) 1989-10-20 2000-08-23 Kyowa Hakko Kogyo Kabushiki Kaisha Kondensierte Purinderivate
US5117830A (en) 1990-11-08 1992-06-02 Whitby Research, Inc. Method of determining viability of tissue
US5177074A (en) 1991-03-26 1993-01-05 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
MX9300141A (es) 1992-01-13 1994-07-29 Smithkline Beecham Corp Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
EP0624159B1 (de) 1992-01-13 1998-11-25 Smithkline Beecham Corporation Pyridyl-substituierte imidazole
EP0607373B1 (de) 1992-06-15 1997-03-19 Celltech Therapeutics Limited Trisubstituierte phenylderivate als selektive phosphodiesterase iv inhibitoren
PL307265A1 (en) 1992-07-28 1995-05-15 Rhone Poulenc Rorer Ltd Compounds containing a phenyl group bonded with aryl or heteroaryl group through their bonding aliphatic group or that containing heteroatom
GB9222253D0 (en) 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
DK0672031T3 (da) 1992-12-02 2003-06-10 Pfizer Catecholdiethere som selektive PDE IV-inhibitorer
GB9226830D0 (en) 1992-12-23 1993-02-17 Celltech Ltd Chemical compounds
TW263495B (de) 1992-12-23 1995-11-21 Celltech Ltd
GB9304919D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304920D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
DE4309969A1 (de) 1993-03-26 1994-09-29 Bayer Ag Substituierte heteroanellierte Imidazole
GB9312853D0 (en) * 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
FI951367A (fi) 1994-03-28 1995-09-29 Japan Energy Corp Puriinijohdannaiset ja tulehdustautien tukahduttajat (suppressantit)
US5869486A (en) 1995-02-24 1999-02-09 Ono Pharmaceutical Co., Ltd. Fused pyrimidines and pyriazines as pharmaceutical compounds

Also Published As

Publication number Publication date
BR9815171A (pt) 2000-10-10
AU1815999A (en) 1999-07-05
HUP0100417A3 (en) 2002-04-29
JP3504234B2 (ja) 2004-03-08
AU1820899A (en) 1999-06-28
EP1044201A1 (de) 2000-10-18
DE19882892T1 (de) 2001-02-22
AU1722899A (en) 1999-07-05
JP2002508376A (ja) 2002-03-19
BR9815169A (pt) 2000-10-10
BR9815170A (pt) 2000-10-10
US6057445A (en) 2000-05-02
CN1281458A (zh) 2001-01-24
TR200001706T2 (tr) 2000-11-21
EP1045849A4 (de) 2001-10-31
JP2001525412A (ja) 2001-12-11
GB2346878B (en) 2002-12-04
JP2002508378A (ja) 2002-03-19
CA2313150A1 (en) 1999-06-17
WO1999031105A1 (en) 1999-06-24
EP1044201A4 (de) 2001-10-31
CA2314335A1 (en) 1999-06-24
US6211367B1 (en) 2001-04-03
HUP0301166A2 (en) 2003-08-28
GB2346879B (en) 2002-12-04
WO1999031104A1 (en) 1999-06-24
ATE244243T1 (de) 2003-07-15
GB2346878A (en) 2000-08-23
KR20010032681A (ko) 2001-04-25
NO20002998D0 (no) 2000-06-09
KR100349385B1 (ko) 2002-08-24
WO1999031102A1 (en) 1999-06-24
JP2002508379A (ja) 2002-03-19
EP1045849B1 (de) 2003-07-02
GB0013780D0 (en) 2000-07-26
GB0013781D0 (en) 2000-07-26
CN1284077A (zh) 2001-02-14
EP1045850A4 (de) 2001-10-31
DE69816127D1 (de) 2003-08-07
CA2313004A1 (en) 1999-06-24
WO1999031103A1 (en) 1999-06-24
DE19882893T1 (de) 2001-02-22
KR20010033049A (ko) 2001-04-25
PT1045849E (pt) 2003-11-28
PL341108A1 (en) 2001-03-26
JP2002508377A (ja) 2002-03-19
HUP0100305A2 (hu) 2002-01-28
US6040447A (en) 2000-03-21
AU1722999A (en) 1999-07-05
HUP0100417A2 (hu) 2001-12-28
EP1045850A1 (de) 2000-10-25
US6228859B1 (en) 2001-05-08
WO1999029694A1 (en) 1999-06-17
DK1045849T3 (da) 2003-10-27
EP1045849A1 (de) 2000-10-25
DE69816127T2 (de) 2004-04-22
ES2202924T3 (es) 2004-04-01
KR20010032979A (ko) 2001-04-25
AU747366B2 (en) 2002-05-16
US6037470A (en) 2000-03-14
AU1723099A (en) 1999-07-05
CN1294590A (zh) 2001-05-09
GB2346879A (en) 2000-08-23

Similar Documents

Publication Publication Date Title
NO20002998L (no) Purinderivater som har fosfodiesterase IV inhibisjonsaktivitet
TR200100241T2 (tr) Nosiseptin reseptörü ORL-1 için yüksek çekim gücü olan ligandlar
EP1659111A3 (de) Piperidinderivate verwendbar als ccr5 antagonisten
BR9814747A (pt) Derivados pleuromutilina atuando comoantimicrobianos
DK0879820T3 (da) Benzamidanaloger anvendelige som PARP (ADP-Ribosyltransferase, ADPRT) DNA-reparations enzyminhibitorer
CA2382919A1 (en) Bicyclic imidazo-3-yl-amine derivatives
DK1401837T3 (da) Purinderivater som A2B-adenosinreceptorantagonister
HK1003708A1 (en) Peripheral vasodilating agent containing n-acylated 4-amino piperidine derivatives as active ingredients
CA2116782A1 (en) 1-substituted 1h-imidazo¬4,5-c|quinolin-4-amines; intermediate and pharmaceutical compositions
CA2387533A1 (en) Purine derivatives
EP2258366A3 (de) Zur Hemmung der Autophosphorylierung von Hepazotyten-Wachstumsfaktorrezeptoren fähige Chinolin- und Chinazolinderivate und diese enthaltende pharmazeutische Zusammensetzungen
CA2387531A1 (en) Purine derivatives
CA2379786A1 (en) Purine derivatives
EP1548008A4 (de) Verbindung mit tgf-beta-hemmender wirkung und diese enthaltende medizinische zusammensetzung
HRP20080052T3 (en) Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation
AU5699399A (en) Pyridyl-bridgehead derivatives and their analogues, pharmaceutical compositions and their use as inhibitors of nicotinic cholinergic receptors
NO20040881L (no) Orale antidiabetes midler.
BR0308592A (pt) Derivados de piperidina ou 8-azabiciclo [3.2.1] oct-3-il-piperidina, de utilidade como moduladores da atividade do receptor de quimocina (especialmente ccr5)
WO2000068198A3 (en) Heterosubstituted pyridine derivatives as pde 4 inhibitors
CA2238875A1 (en) Tri-aryl ethane derivatives as pde iv inhibitors
AU2267495A (en) Benzamide derivatives as vasopressin antagonists
WO2003008365A3 (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
TR200000153T2 (tr) İl-5 inhibite eden 6-azaurasil türevleri.
WO2003082881A3 (en) Pyridoxal-5-phosphate derivatives as hiv integrase inhibitors
AU2001278708A1 (en) Adenosine derivatives and use thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application